PaySign, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting results for both the three-month and nine-month periods ended on that date.

Key Highlights

  • Total revenues of $30,800,158 for the three months ended September 30, 2026, compared to $21,596,478 in the same period of 2025, according to the filing.
  • Pharma industry revenues of $16,620,579 for the third quarter of 2026, up from $7,920,604 in the third quarter of 2025, as reported in the condensed consolidated statements of operations.
  • Net income of $6,735,694 for the three months ended September 30, 2026, compared to $2,215,135 in the prior-year quarter.
  • Nine-month net income of $18,931,149 for the period ended September 30, 2026, versus $6,188,996 for the same period in 2025.
  • Total stockholders' equity of $66,354,762 as of September 30, 2026, up from $48,490,171 at December 31, 2025.
  • Cash of $34,539,557 as of September 30, 2026, compared to $21,067,651 at December 31, 2025, per the balance sheet.

PaySign's Pharma and Plasma Segments Drive Third-Quarter Revenue Growth

According to the filing, PaySign, Inc. (NASDAQ:PAYS), a Nevada-incorporated company headquartered in Henderson, Nevada, operates across two primary revenue segments: the plasma industry and the pharma industry, alongside a smaller "Other" category. For the three months ended September 30, 2026, plasma industry revenues were $13,826,621, compared to $12,860,478 in the same quarter of 2025. Pharma industry revenues reached $16,620,579, more than doubling from $7,920,604 reported in Q3 2025. The company's total revenues for the third quarter of 2026 were $30,800,158, up from $21,596,478 in the prior-year quarter.

The filing disclosed gross profit of $19,919,858 for the three months ended September 30, 2026, against cost of revenues of $10,880,300. Total operating expenses for the quarter were $12,600,234, comprising selling, general and administrative expenses of $10,291,131 and depreciation and amortization of $2,309,103. Income from operations was $7,319,624 for the quarter, compared to $1,581,951 in Q3 2025. Net income per share on a diluted basis was $0.11 for the three months ended September 30, 2026, based on weighted average diluted shares of 62,719,220, as reported in the statements of operations.

For the nine months ended September 30, 2026, the filing reported total revenues of $87,090,653, up from $59,272,980 in the nine months ended September 30, 2025. Nine-month pharma industry revenues were $46,949,164, compared to $24,293,163 in the prior-year period. The balance sheet reflected total assets of $347,474,190 as of September 30, 2026, against total liabilities of $281,119,428, with retained earnings of $34,010,760. The company's stock-based compensation expense for the nine-month period was $3,892,007, per the cash flow statement.

What Was Disclosed

PaySign, Inc. filed a Form 10-Q for the quarterly period ended September 30, 2026, disclosing unaudited condensed consolidated financial statements covering revenue by segment, net income, balance sheet positions, and stockholders' equity activity for the three- and nine-month periods ending on that date.